Шаблоны LeoTheme для Joomla.
GavickPro Joomla шаблоны

Case Report

Neuroleptic Malignant Syndrome and Dantrolene. A Case Report

Gustavo Cruz Suarez MD1*, Sergio Jaramillo MD1, Beatriz Sanchez MD1, Fredy Ariza MD1, Angy Cruz MD1

1Department of Anesthesia and Perioperative Medicine, Fundación Valle del Lili, Cali, Colombia.

*Corresponding author: Dr. Gustavo Cruz Suarez, Department of Anesthesia and Perioperative Medicine, Fundación Valle del Lili, Cali, Colombia, Tel: 3165267595; Fax: 3319090; Email: gustavocruzsuarez@hotmail.com

Submitted: 05-27-2015 Accepted: 07 -28-2015 Published: 08-19-2015

Download PDF





Neuroleptic malignant syndrome is a rare condition; manifestations include severe autonomic dysfunction, hyperthermia and muscle rigidity, among others. This may occur in response to drugs that interact with dopaminergic pathways. Diagnosis of this syndrome is mainly clinical since there is no specific laboratory test for this condition and it has a high mortality rate given its multiorgan involvement. This is a case report of a patient who developed neuroleptic malignant syndrome that was managed with supportive therapy and dantrolene.


First description of neuroleptic malignant syndrome (NMS) was made in 1960 by Delay, who referred this event related to neuroleptics exposition as “akinetic hypertonic syndrome” [1]. This rare condition can be presented as an adverse reaction to the use of some antipsychotics and other medications, which interact with neuronal dopaminergic pathways. Clinical features include severe autonomic dysfunction, hyperthermia, and muscular rigidity, among others. Given its unusual presentation and a high mortality rate, it is important to make an opportune diagnosis in order to establish a prompt management [2-4]. In this case report, we present a patient with cancer who developed NMS after metoclopramide/ haloperidol administration and his clinical evolution with treatment based on dantrolene and supportive measures.

Case Description

A 48-year-old male patient was admitted to our hospital with diagnosis of papillary cancer of unknown primary origin with metastatic compromise of the right eye tissues, cervical ganglia, thyroid and parathyroid glands. Patient was presented with pain and several edema along the right side of the face and neck associated with peripheral vertigo. Complementary tests were made during first days and supportive measures were initiated based on methadone 10 mg OD/8h, morphine 6 mg IV/6h, amitriptyline 25 mg per day, and metoclopramide 10 mg IV/ 8 h.

Twelve days after admission and after administration of metoclopramide, the patient turned anxious and disoriented with progression to psychomotor agitation. As vital signs were stable and no desaturation was present, he received supplementary oxygen by nasal cannula (SaO2 93%) and haloperidol 5 mg intramuscular; minutes later the patient turned aggressive, with visual and hearing hallucinations, paranoid delirium, muscular rigidity and diaphoresis. Midazolam intramuscular was initially administered without adequate response.

Patient status progressed to respiratory failure because of airway obstruction due to swelling of compromised neck tissues, trismus, and generalized rigidity; nasotracheal intubation guided by fibrobroncoscopy and admission to intensive care unit was decided (fig1). During transportation the patient presenting worsening of muscular rigidity, transient tonic clonic movements, tachycardia (160 hbm), hypotension (60/30 mmHg) with poor response to intravenous fluids and hyperthermia (390C). CO2 end tidal by capnography reported a value of 33 mmHg. A femoral central venous catheter was inserted and a norepinephrine infusion was started with progressive increases until a rate at 0,5 mcg/ Kg/min. Initial arterial blood gases showed a severe metabolic acidosis (pH 7.09, pCO2 30 mmHg, pO2 103 mmHg, EB -20, HCO3 9.3 mmol/L) and hyperlactatemia (17 mmol/L).

anesthesia fig 7.1

Figure 1. Airway difficult for edema on the right side of the face and neck.

anesthesia fig 7.2

Figure 2. Rhabdomyolysis evidenced by elevation of creatine phosphokinase(CPK).

anesthesia fig 7.3

Figure 3. Decrease lactic acid 6 hours after starting dantrolene.

This clinical scenario, led us to suspect a NMS and a bolus of dantrolene 20 mg IV in 20 minutes was administered, obtaining a dramatic positive response. Vasopressor infusion was suspended in less than eight minutes and cardiac frequency lowered to 90 bpm. A high rate of cold intravenous Ringer’s lactated was achieved (3000 ml/h) in combination with other cooling measures and dantrolene 20 mg /bicarbonate 1 mEq/Kg/h by continuous separate IV infusions was maintained over the next hour.

Hemodynamic stability of the patient was maintained without new requirements of vasopressors. Control arterial blood gases at 4 hours reported pH 7.37; pCO2 35mmHg; pO2 163mmHg; HCO3 20mEq/L; EB -4.9; sO2 99% and lactic acid 2.4 mmol/L. Rhabdomyolisis occurred as evidenced by peak levels of CPK reached at first 24 hours after event. Despite of severe initial lactic acidosis was resolved during first 6 hours, high seric levels of transaminases persisted until two weeks (Fig. 2-4). During this period, extubation was achieved (7th day). The patient was discharged at 24th day without other complications.

anesthesia fig 7.4

Figure 4. Liver injury with transaminase levels peak on the third day.


NMS is a serious, infrequent and morbid condition with a high mortality rate (10-20%) [2]. Its incidence reported around the world is variable (0,07% [3] – 2,2% [4]) because there are no accepted universal criteria and its exclusion diagnosis nature, among others [5]. The first approximation to diagnostic criteria and definition of NMS was an expert consensus meeting in 2011 that used Delphi’s methodology [6]. DSM-IV-TR criteria indicates that muscular rigidity and hyperthermia must be present after the administration of antipsychotic drugs before consider this diagnosis; probability increases when the elevation of the CPK is present [7]. Our patient presented these signs preceded by neurologic symptoms. This observation is congruent with retrospective studies indicating that these neurological symptoms are present before systemic alterations in more than 80% of the cases [8,9].

Our case reflects a clear history of exposure to a medication that could precipitate NMS, with activation of a severe rhabdomyolisis as measured CPK levels show. Secondary acidosis with hyperlactatemia, liver dysfunction, and secondary kidney injury (fig2-4) responded to medical treatment based on dantrolene and fluid management without requirement of renal support therapy.

Differential diagnosis of NMS includes infectious, toxic (anticholinergic syndrome, serotoninergic syndrome, drug abuse), endocrine ( pheocromocitome, thyrotoxicosis) and other psychiatric entities (catatonia, delirium, no convulsive epileptic state, among others.) Regarding the physiopathology of NMS, various hypothesis have related it with inhibition of dopaminergic pathways. This could explain the development of hyperthermia associated to blocking of its receptors in the hypothalamus and muscular rigidity by blockade of the same family of receptors at the corpus striatum. This theory is supported by other papers referring the fact that drugs like amantadine [10] and Bromocriptine [11], could be benefit.

Other authors have suggested a possible relation between NMS and primary defects of the escheletic muscle similar to malignant hyperthermia (MH), suggesting a possible common etiology between these two hypercatabolic disorders [12]. Unfortunately, ulterior studies have not confirmed this theory, and more yet have shown contradictory results.. Caroff and Colleges discovered that 5/7 patients with NMS were susceptible of MH [13], as opposed to Krivosic-Horber who reported no demonstrable association [14]. Another possible explanation of NMS proposes an immunologic origin [15], A systemic and massive response to tissue injury known as “ acute answer phase” is classically developed with leukocytosis and elevation of muscular enzymes [16]. This phenomena also happens in MNS as we reported in this patient. When MNS development risk factors have been analyzed, it seems to be no relation with age, gender, time of exposition or dose of psychotropics [17]. Instead, polipharmacy and the type of antipsychotic (first vs. last generation), have been associated as occurred in our patient where metoclopramide and haloperidol were used [18].

Management of NMS involves stopping of the probable causal drug, and suspending of other anti-serotoninergic drugs, even lithium and/or valproic-acid if concomitantly used [19]. hydroelectrolitic support by balanced fluids to achieve current established microcirculatory and metabolic goals and early decision for renal and ventilatory support are needed to assure survival and decrease the chance of bad outcomes. Electroshock therapy has been reported, indicated as the first line therapy when it is not possible to disregard catatonia or people who do not respond in the first week of treatment [20,21].

Dantrolene (a calcium blocker) has been used since 1976 [22] as the cornerstone for the treatment of human malignant hyperthermia and more recently for NMS with success. Coons et al has suggested that dandrolene could act as modulator of catabolic response seen in this syndrome [23].

It has been sugested that NMS is a neurogenic form of malignant hipertermia (MH), and the rol of the Ryanodine Receptor type 1 gene (RYR1) mutations could be envolved on the development of NMS [24]. The pathophysiolgy of NMS still elusive, how ever, the treatment of NMS with Dantrolene is known to be useful due to the restriction of neuronal hiperactivity because it reduces internal Ca2+ flux within nerve cells, and limits the adverse effects of excessive SNS inputs on Ca2+ regulation within skeletal muscle [25]. In skeletal muscle, dantrolene sodium dissociates the excitation-contraction coupling, probably by interfering with the release of Ca++ from the sarcoplasmic reticulum, being this associated with loss of grip strength and weakness of the extremities as well as drowsiness and dizziness. The biologic half-life after intravenous administration is between 4 to 8 hours, it bounds to plasma proteins, mostly albumin. The recommended prophylactic dose of is 2.5 mg/ kg, the continous infusion beggins at a minimum dose of 1 mg/kg, until symptoms subside or the maximun dose of 10 mg/kg has been reached. The adverse effects observed with high doses are depressant effect on gastrointestinal smooth muscles, There have been reports of thrombophlebitis following administration of intravenous dantrolene, and site reactions and tissue necrosis secondary to extravasation. Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy [25,26].

Our patient received dantrolene and improved dramatically as we reported in spite of markers of acidosis and rhabdomyolisis that return to usual values 24-48 hours later.

In summary, we presented a case of NMS, a serious condition characterized by fast instauration of neurological, metabolic and hemodynamic compromises, that could be triggered by antyphsychotic drugs and other dopaminergic blockers. Classically, neurological symptoms precede systemic alterations resulting of value for diagnosis and exclusion of other etiologies. As unusual, NMS may be difficult to be diagnosed by physicians who not familiarized, with delays in adequate and focused treatment. Besides supporting therapies, dantrolene emerges as a highly effective alternative to blunt hypercatabolic response in advance to promptly return to hemodynamic stability and adequate systemic oxygen delivery. We would like to alert institutions around the world about availability of dantrolene or, at least, an inter-institutional collaborative network allowing rapid access to this drug.



1.Delay J, Pichot P, Lempiere T, Blissalde B, Peigne F. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol. 1960, 118(1): 145-152.

2.Susman VL, Addonizio G. Recurrence of neuroleptic malignant syndrome.Actas Esp Psiquiatr. J Nerv Ment Dis. 1988, 176(4): 234-241.

3.Gelenberg AJ, Bellinghausen B, Wojcik JD, Falk WE, SachsGS. A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatr. 1988, 145(4): 517-518.

4.Hermesh H, Aizenberg D, Lapidot M, Munitz H. Risk of malignant hyperthermia among patients with neuroleptic malignant syndrome and their families. Am J Psychiatr. 1988, 145(11): 1431-1434.

5.Jeffrey R, Paul E. Neuroleptic Malignant Syndrome. Am J Psychiatry. 2007, 164: 166.

6.Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011, 72(9): 1222-1228.

7.Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatr. 1985, 142: 1137-1145.

8.Stanley N. Caroff, MD. Neuroleptic malignant syndrome: Still a risk, but which patients may be in danger?: American Psychiatric Publishing Inc. 2003, 2(12): 1-44.

9.Velamoor VR, Norman RM, Caroff SN, Mann SC, Sullivan KA et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994, 182(3): 168–173.

10.McCarron MM, Boettger ML, Peck JI. A case of neuroleptic malignant syndrome successfully treated with amantadine. J Clin Psychiatr. 1982; 43(9): 381-382.

11.Bond WS. Detection and management of the neuroleptic malignant syndrome. Clin Pharmacol. 1984, 3(3): 302- 307.

12.Tollefson G. A case of neuroleptic malignant syndrome: in vitro muscle comparison with malignant hyperthermia. J Clin Psychopharmacol. 1982, 2(4): 266-270.

13.Caroff SN, Rosenberg H, Fletcher JE, Heiman-Patterson TD, Mann SC. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology. 1987; 67(1): 20-25.

14.Adnet PJ, Krivosic-Horber RM, Adamantidis MM, Haudecoeur G, Adnet-Bonte CA et al. The association between the neuroleptic malignant syndrome and malignant hyperthermia. Acta Anaesthesiol Scand. 1989, 33(8): 676- 80.

15.Rebecca E. Anglin, Patricia I. Rosebush. Neuroleptic malignant syndrome: neruoimmunologic hypothesis. Cannadian Medical association journal 2010.

16.Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999, 340(6): 448-54.

17.Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000, 85: 129–135.

18.Su Y-P, Chang C-K, Hayes RD, Harrison S, Lee W et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta psychiatr Scand. 2014, 130(1): 52-60.

19.Verma R, Junewar V. An atypical case of neuroleptic malignant syndrome precipitated by valproate. BMJ case Rep. 2014.

20.Verdura Vizcaíno EJ, Ballesteros Sanz D, Sanz-Fuentenebro J. Electroconvulsive therapy as treatment for malignant neuroleptic syndrome. Rev Psiquiatr Salud Ment. 2011, 4(3): 169-176.

21.Hitesh N Pandya, Michael J Keyes, Brian C Christenson. Electroconvulsive Therapy in a Schizophrenic Patient with Neuroleptic Malignant Syndrome and Pulmonary Embolism: A Case Report. Psychiatry (Edgmont). 2007, 4(4): 21.

22.Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology. 1982, 56(4): 254–262.

23.Coons DJ, Hillman FJ, Marshall R W. Treatment of neuroleptic malignant syndrome with dantrolene sodium A case report. Am J Psichiatry. 1982, 139(7): 944-945.

24.Takako Sato, Hajime Nishio, Misa Iwata, KentoTsuboi, Akiyoshi Tamura et al. Postmortem molecular screening for mutations in ryanodine receptor type 1 (RYR1) gene in psychiatric patients suspected of having died of neuroleptic malignant syndrome. Forensic Science International. 2010, 194 (1-3) 77–79.

25.Ronald J Gurrera. Is Neuroleptic Malignant Syndrome a Neurogenic Form of Malignant Hyperthermia? Clinical Neuropharmacology. 2010, 25(4): 183–193.

26.Gamble Pharmaceuticals,TM Owner, Cincinati, Ohio 45202. 2007.

Cite this article: Suarez G C. Neuroleptic Malignant Syndrome and Dantrolene. A Case Report. J J Anes Res. 2015, 2(1): 007.

Contact Us:
TRAIL # 150 W
E-mail : info@jacobspublishers.com
Phone : 512-400-0398